These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24132751)

  • 21. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
    Jandial DD; Farshchi-Heydari S; Larson CA; Elliott GI; Wrasidlo WJ; Howell SB
    Clin Cancer Res; 2009 Jan; 15(2):553-60. PubMed ID: 19147760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the Copper Transport System to Improve Treatment Efficacies of Platinum-Containing Drugs in Cancer Chemotherapy.
    Kuo MT; Huang YF; Chou CY; Chen HHW
    Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34201235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platinum transfer from hCTR1 to Atox1 is dependent on the type of platinum complex.
    Wu X; Yuan S; Wang E; Tong Y; Ma G; Wei K; Liu Y
    Metallomics; 2017 May; 9(5):546-555. PubMed ID: 28383086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model.
    Kim KI; Jang SJ; Park JH; Lee YJ; Lee TS; Woo KS; Park H; Choe JG; An GI; Kang JH
    J Nucl Med; 2014 Oct; 55(10):1692-8. PubMed ID: 25091475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
    Holzer AK; Katano K; Klomp LW; Howell SB
    Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
    Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
    Oncotarget; 2016 Aug; 7(31):49310-49321. PubMed ID: 27384479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule-stabilizing effect.
    Yu H; Wang H; Qie A; Wang J; Liu Y; Gu G; Yang J; Zhang H; Pan W; Tian Z; Wang C
    Cancer Sci; 2021 Nov; 112(11):4655-4668. PubMed ID: 34533854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin.
    Larson CA; Adams PL; Jandial DD; Blair BG; Safaei R; Howell SB
    Biochem Pharmacol; 2010 Aug; 80(4):448-54. PubMed ID: 20451502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner.
    Kurokawa T; He G; Siddik ZH
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):427-36. PubMed ID: 19529937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of copper transporters in resistance to platinating agents.
    Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Copper-dependent recycling of hCTR1, the human high affinity copper transporter.
    Molloy SA; Kaplan JH
    J Biol Chem; 2009 Oct; 284(43):29704-13. PubMed ID: 19740744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stable plasma membrane levels of hCTR1 mediate cellular copper uptake.
    Eisses JF; Chi Y; Kaplan JH
    J Biol Chem; 2005 Mar; 280(10):9635-9. PubMed ID: 15634665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
    Howell SB; Safaei R; Larson CA; Sailor MJ
    Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rate and regulation of copper transport by human copper transporter 1 (hCTR1).
    Maryon EB; Molloy SA; Ivy K; Yu H; Kaplan JH
    J Biol Chem; 2013 Jun; 288(25):18035-46. PubMed ID: 23658018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
    Dmitriev OY
    Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer.
    Cai H; Wu JS; Muzik O; Hsieh JT; Lee RJ; Peng F
    J Nucl Med; 2014 Apr; 55(4):622-8. PubMed ID: 24639459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Basic Research of the Adenovirus-mediated
    Wu XL; Guo T; Cai HW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):34-38. PubMed ID: 29737086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
    Kabolizadeh P; Ryan J; Farrell N
    Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1).
    Quail JF; Tsai CY; Howell SB
    J Trace Elem Med Biol; 2014 Apr; 28(2):151-159. PubMed ID: 24447817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.
    Leonhardt K; Gebhardt R; Mössner J; Lutsenko S; Huster D
    J Biol Chem; 2009 Mar; 284(12):7793-802. PubMed ID: 19141620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.